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Background. Escherichia coli O25b:H4-ST131 represents a predominant clone of multidrug-resistant uropatho-
gens currently circulating worldwide in hospitals and the community. Urinary tract infections (UTIs) caused by
E. coli ST131 are typically associated with limited treatment options and are often recurrent.
Methods. Using established mouse models of acute and chronic UTI, we mapped the pathogenic trajectory of
the reference E. coli ST131 UTI isolate, strain EC958.
Results. We demonstrated that E. coli EC958 can invade bladder epithelial cells and form intracellular bacterial
communities early during acute UTI. Moreover, E. coli EC958 persisted in the bladder and established chronic UTI.
Prophylactic antibiotic administration failed to prevent E. coli EC958–mediated UTI. However, 1 oral dose of a
small-molecular-weight compound that inhibits FimH, the type 1 fimbriae adhesin, significantly reduced bacterial
colonization of the bladder and prevented acute UTI. Treatment of chronically infected mice with the same FimH
inhibitor lowered their bladder bacterial burden by >1000-fold.
Conclusions. In this study, we provide novel insight into the pathogenic mechanisms used by the globally dis-
seminated E. coli ST131 clone during acute and chronic UTI and establish the potential of FimH inhibitors as an
alternative treatment against multidrug-resistant E. coli.
Keywords. E. coli ST131; uropathogenic E. coli; urinary tract infection; antibiotic resistance; type 1 fimbriae;
mannoside; biofilm.
Uropathogenic Escherichia coli (UPEC) causes the ma-
jority (approximately 80%) of urinary tract infections
(UTIs), resulting in an estimated 150 million cases
globally per year [1]. Women are primarily affected,
with almost 50% expected to experience 1 UTI in their
lifetime and 20%–30% experiencing a recurrence within
6 months of an acute episode [2]. Recurrent UTI con-
tributes significantly to UTI-associated morbidity and
heavily imposes on public health resources [3]. The
overwhelming success of antibiotics has led to the com-
monly held belief that cystitis is a self-limiting disease.
However, placebo-controlled studies indicate that the
natural course of cystitis can last for weeks in approxi-
mately half of all patients [4, 5]. Furthermore, many
individuals have chronic recurrent UTI and require sup-
pressive antibiotic therapy to prevent frequent recur-
rences. While, for the majority of cases, a short course
of antibiotic therapy still remains an effective treatment,
antibiotic resistance among UPEC strains is continually
increasing. Despite large variation in UPEC antibiotic
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resistance rates between different countries and among differ-
ent UTI patient cohorts, large surveillance studies conducted
during the last 20 years across Europe, North America, and
South America highlight that 20%–50% of UPEC strains can be
resistant to commonly prescribed antibiotics, such as
trimethoprim-sulfamethoxazole(TMP-SMZ),fluoroquinolones,
and β-lactams [3]. This trend has led to an increased rate of
treatment failure with standard antibiotic therapies and the in-
creased use of second- and third-line therapies, further promo-
ting the emergence of multidrug-resistant UPEC. Taken together,
the increasing antibiotic resistance among UPEC strains and the
paucity of new antibiotics in development threaten to greatly com-
plicate UTI management in the near future.
UPEC infection proceeds through a well-described pathogenic
pathway in the lower urinary tract [6]. Numerous UPEC viru-
lence factors, including adhesins, toxins, and iron-acquisition
systems, have been identified [7]. Type 1 fimbriae mediate host-
pathogen interactions critical in pathogenesis. The FimH
adhesin, located at the tip of type 1 fimbriae, binds to mannosy-
lated glycoproteins on human and mouse bladder epithelial
cells and facilitates UPEC colonization and invasion of the
bladder epithelium (urothelium) [8, 9]. After invasion, UPEC
can escape the endocytic vesicle and rapidly replicate within the
urothelial cell cytoplasm, forming intracellular bacterial com-
munities (IBCs) that resemble biofilms [10, 11]. IBC formation
occurs primarily during acute bladder infection and allows bac-
teria to rapidly expand in numbers and establish infection in a
host niche that is protected from neutrophil attack and antibi-
otics [12–14]. The IBC pathogenic cascade has been extensively
characterized in a murine model of cystitis [15, 16], and exfoli-
ated bladder epithelial cells containing IBCs have been signifi-
cantly observed in urine from women with recurrent UTI but
not from healthy controls [17]. Animal models have defined 2
distinct chronic outcomes to experimental UPEC infection of
the bladder in immunocompetent hosts: spontaneous resolu-
tion of bacteriuria that is often accompanied by a persistent
latent intracellular infection (ie, a quiescent intracellular reser-
voir [QIR]) [16] or by chronic cystitis [6]. UPEC within QIRs
can reemerge months later to seed a recurrent infection [16].
On the other hand, the development of chronic cystitis can sen-
sitize mice to recurrent UTI when they are challenged with a
new bacterial strain after clearance of infection following antibi-
otic treatment [18]. Thus, UPEC can effectively colonize the host
bladder and establish acute, chronic, or recurrent infections.
On the basis of murine models that mimic aspects of human
disease, FimH is critical for UPEC pathogenesis. FimH is also
under positive selection in human clinical isolates of UPEC,
further supporting its role in human disease [19]. Inhibiting
FimH function may thus represent a therapeutic strategy for the
treatment and prevention of UTI. In this respect, novel biaryl
mannoside FimH inhibitors, including compound ZFH-04269
(4′-[a-D-Mannopyranosyloxy]-N,3′-dimethylbiphenyl-3-carbox
amide), were recently shown to attenuate UPEC virulence in
miceby impedingFimHbinding to thebladderepithelium, there-
by preventing bacterial invasion and IBC formation and result-
ing in significantly reduced bladder bacterial titers during both
acute and chronic cystitis [20, 21].
Recently, a clone of UPEC belonging to serotype O25b:H4
and sequence type 131 (E. coli ST131) has emerged as a leading
multidrug-resistant pathogen causing urinary tract and blood-
stream infections in hospitals and the community. Several
reports have demonstrated the global distribution of this
lineage, indicating that it constitutes a major threat to public
health worldwide [22]. The successful dissemination of E. coli
ST131 is thought to be due to a combination of antibiotic resis-
tance and virulence. E. coli ST131 commonly harbor genes en-
coding several types of β-lactamases, particularly of the CTX-M
family of extended-spectrum β-lactamases (ESBLs), and are
typically associated with limited treatment options [23–26].
While the E. coli ST131 genes conferring resistance to multiple
classes of antibiotics have been the focus of many recent
studies, the virulence mechanisms used by this clone are less
well understood. Although E. coli ST131 strains are derived
from phylogenetic group B2, which includes several character-
ized pathogenic E. coli clonal groups, only a few virulence genes
(eg, fimH, iutA, and sat) appear to be uniformly encoded in all
E. coli ST131 strains [24, 25, 27, 28]. Clinical studies have dem-
onstrated transmission of virulent E. coli ST131 strains between
family members [29, 30], but the factors that contribute to the
widespread dissemination of this lineage and the pathogenic
mechanisms used during UTI remain poorly defined.
We have previously demonstrated that the genome sequence of
a representative multidrug-resistant UPEC ST131 isolate, E. coli
EC958, contains genes encoding a variety of potential virulence
factors, including numerous adhesins, autotransporters, and side-
rophore receptors [28]. In this study, we examined the pathogenic
lifestyle of E. coli EC958 during experimental UTI in mice with
acute and chronic infection. We demonstrated that E. coli EC958
is able to invade the bladder epithelium and form IBCs. In addi-
tion, we showed that E. coli EC958 can persist in the bladder and
establish chronic infection. We also demonstrated a key role for
type 1 fimbriae in the ability of E. coli EC958 to establish bladder
infection, as prophylactic treatment with an oral FimH inhibitor
prevented acute cystitis. Moreover, a single oral dose of the same
FimH inhibitor significantly reduced the bacterial load in the
bladder of mice chronically infected with E. coli EC958. This
study revealed the potential of FimH inhibitors as an alternative
treatment against multidrug-resistant UPEC strains.
METHODS
Bacterial Strains and Culture Conditions
E. coli EC958 was isolated from the urine of a patient present-
ing with community UTI in the northwest region of England
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and is a representative member of the United Kingdom epi-
demic strain A (pulsed-field gel electrophoresis type), one of
the major pathogenic lineages causing UTI across the United
Kingdom [31]. E. coli EC958 is a multidrug-resistant phyloge-
netic group B2 strain of serotype O25b:H4 and sequence type
131; its genome sequence has been recently determined [28].
For mouse infections, E. coli EC958 was typically cultured in
Luria broth (LB) under type 1 fimbriae–inducing conditions
(ie, 3 sequential 24-hour cultures incubated statically at 37°C).
Functional expression of type 1 fimbriae by E. coli EC958 was
confirmed by agglutination of yeast cells (Saccharomyces cerevi-
siae) as previously described [32].
Mouse Infections With E. coli ST131
All animal experimentation was conducted following the Nation-
al Institutes of Health guidelines for housing and care of laborato-
ry animals and was performed in accordance with institutional
regulations after pertinent review and approval by the Animal
Studies Committee at Washington University School of Medi-
cine. C3H/HeN mice were obtained from Harlan Sprague
Dawley (Indianapolis, IN). The mouse model of UTI was used as
previously described [18]. Briefly, 7–8-week-old female C3H/
HeN mice were inoculated with 2 × 107 colony forming units
(CFU; acute infection) or 2 × 108 CFU (chronic infection) of E.
coli EC958 directly into the bladder by transurethral catheteriza-
tion. Bacterial titers in mouse urinary tract tissues were quantified
by aseptically removing the bladder and kidneys at the time of
euthanization, homogenizing the organs in phosphate-buffered
saline (PBS), and plating serial dilutions on LB agar. In chronic
infections, longitudinal urinalysis was performed prior to infec-
tion and at 1, 3, 7, 10, 14, 21, and 28 days after infection by urine
collection and plating serial dilutions on LB agar.
Detection of E. coli ST131 IBCs
Bladders of C3H/HeN mice infected with E. coli EC958 were
bisected, splayed, and fixed in 3% paraformaldehyde for 1 hour.
For IBC enumeration, fixed bladders were washed and stained
with 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal)
as previously described [33]. IBC size and morphology were ex-
amined by immunofluorescence and confocal laser scanning
microscopy [34].
FimH Inhibitor Studies
Preparation and pharmacokinetic analysis of the FimH inhibitor
4′-(a-D-Mannopyranosyloxy)-N,3′-dimethylbiphenyl-3-carboxa-
mide (compound ZFH-04269) has been previously described
(compound 8 in [21]). One oral dose (50 mg/kg) of compound
ZFH-04269 was administered to mice by oral gavage either 30
minutes prior to transurethral inoculation with E. coli EC958
(prophylactic therapy) or on day 14 after infection (treatment of
chronic cystitis).
Statistical Analyses
Bacterial numbers in urinary tract tissues (bladder and kidneys)
were compared between different groups of mice, using non-
parametric tests; the Mann–Whitney U test was used to com-
pare median bacterial titers between 2 groups of mice, and the
Kruskal–Wallis test for comparisons involving ≥3 mouse groups.
A statistical significance threshold was set at P < .05.
RESULTS
E. coli ST131 Cause Acute Infection of the Mouse Urinary Tract.
To map the pathogenesis of E. coli EC958 in vivo, we used a
well-established mouse model of UTI [12]. Eight-week old
C3H/HeN female mice were inoculated with 2 × 107 CFU of
E. coli EC958 directly into the bladder, using a sterile Teflon
catheter. The colonization ability of E. coli EC958 was exam-
ined over the course of acute infection by determining bacterial
CFU in the mouse bladder and kidneys at 6, 16, and 24 hours
after infection (Figure 1). Bladder colonization by E. coli EC958
remained high at all assessed time points of acute infection,
Figure 1. Escherichia coli ST131 causes acute urinary tract infection in female C3H/HeN mice. Scatter plots of E. coli EC958 titers (colony-forming units
[CFU]/organ) in bladders (A) and kidneys (B) of mice at 6, 16, and 24 hours after infection. Horizontal bars represent median E. coli EC958 titers for each
mouse group. A total of 8–10 mice were assessed per time point in each experiment. Plots show data from 2 experimental repeats.
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with group median values of >104 CFU/bladder. By 24 hours
after infection, a bimodal distribution was observed for bacteri-
al titers in the bladder (Figure 1A). The 2 bladder subpopula-
tions observed at 24 hours after infection (each corresponding
to approximately 50% of infected mice) displayed median bac-
terial CFU titers that were 2 logs higher or 2 logs lower than
that observed at 6 hours after infection for all infected mice.
C3H and CBA background mice are known to be genetically
susceptible to vesicoureteral reflux [35], and therefore kidney
colonization by 6 hours after infection has been shown to occur
uniformly in these strains after intravesical inoculation of
UPEC, even under conditions that minimize mechanical reflux
during inoculation [36]. E. coli EC958 was also able to establish
kidney infection with high titers (>105 CFU/kidneys) by 6
hours after infection, and while the kidney bacterial load de-
creased over time, E. coli EC958 was still present in the kidneys
of all infected mice by 24 hours after infection (Figure 1B).
Taken together, our results demonstrate that E. coli EC958 is
able to effectively colonize the bladder and kidneys of C3H/
HeN mice and establish acute infection of the urinary tract.
E. coli ST131 Proceed Through the IBC Pathway During Acute
Bladder Infection
To examine whether E. coli EC958 progresses through IBC de-
velopment during acute bladder infection, the bladders of in-
fected mice were extracted at 6 hours after infection, bisected,
fixed, and stained with X-gal. IBC formation was observed in
all infected bladders, with a median of 21 IBCs/bladder (range,
7–33 IBCs/bladder; Figure 2A), suggesting that E. coli EC958 is
able to invade bladder urothelial cells and replicate intracellu-
larly to form IBCs. Immunofluorescence labeling of E. coli
EC958–infected bladders at 6 hours after infection and exami-
nation by confocal microscopy revealed large IBCs (Figure 2B–
D). By 16 hours after infection, most IBC-containing urothelial
cells had burst and released E. coli EC958 cells, in the form of
free rod-shaped or long filamentous bacteria, into the bladder
lumen (Figure 2E–G). This is the first demonstration of IBC
formation by an E. coli ST131 strain during acute infection of
the mouse bladder.
E. coli ST131 Can Persist in the Bladder and Cause Chronic
Infection
Previous studies have shown that acute UTI due to UPEC can
progress to chronic cystitis or infection resolution [18]. In
agreement with these findings, we observed a bimodal distribu-
tion of bladder bacterial titers at 24 hours after infection with
E. coli EC958, suggesting that mice with higher bacterial titers
may develop chronic cystitis. To test whether E. coli EC958 can
persist in the bladder beyond acute infection, we tested its
ability to cause chronic cystitis in female C3H/HeN mice.
Chronic cystitis was previously defined by the presence of high-
titer (>104 CFU/mL) persistent bacteriuria of at least 2-4 weeks
Figure 2. Escherichia coli ST131 progresses through the intracellular bacterial community (IBC) pathway during acute bladder infection in female C3H/
HeN mice. A, Scatter plot of IBC number per bladder for 15 mice infected with E. coli EC958 at 6 hours after infection. IBCs were stained with X-gal as
described elsewhere [33] and counted under a light microscope. Confocal micrographs of IBCs present in the bladder of mice infected with E. coli EC958 at
6 hours after infection (B–D) and 16 hours after infection (E–G). Bacteria were immunostained using rabbit polyclonal anti-E. coli sera (US Biological),
followed by anti-rabbit immunoglobulin G Alexa Fluor 488 (green; Molecular Probes). The bladder luminal surface was stained with WGA-594 (red; Molecu-
lar Probes), and nuclear staining was performed using TOPRO3 (blue; Molecular probes). Stained bladders were mounted on glass slides with ProLong
Gold Antifade reagent (Invitrogen) and examined using a Zeiss LSM510 confocal laser scanning microscope (Thornwood) under a 63× objective.
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duration and high-titer (>104 CFU/organ) bladder colonization
with accompanying inflammation at 2 and 4 weeks after infec-
tion [18]. After experimental inoculation with 107 or 108 CFU
of E. coli EC958, bacterial titers in urine were monitored over a
period of at least 4 weeks (Figure 3A). We found that 2 of 20
mice (10%) and 8 of 20 mice (40%) infected with 107 and 108
CFU of E. coli EC958, respectively, developed high-titer (>104
CFU/mL) bacteriuria that was present at every time point
through day 28 after infection (Figure 3B and 3C). A subset of
mice infected with 108 CFU of E. coli EC958 were euthanized
for analysis at day 28 (n = 10) and day 42 (n = 5) after infection.
We found that the bladders recovered from mice with persistent
bacteriuria (n = 5) were grossly enlarged and inflamed (data not
shown) and had bacterial titers significantly higher than those
of mice that had resolved bacteriuria (ie, mice with <104 CFU/
mL in urine at least once during the infection period; n = 10),
with a median difference in CFU per bladder of approximately
30 000-fold (P = .0026, by the Mann–Whitney U test; Figure 3D).
Bacterial titers in the kidneys were also significantly higher in
persistently bacteriuric mice as compared to those in mice with
resolved bacteriuria, with amedian difference in CFU per kidney
of 10 000-fold observed (P = .0003, by the Mann–Whitney U
test; Figure 3D). Taken together, our results demonstrate that
E. coli EC958 can persist in the bladder of C3H/HeN mice and
cause chronic infection.
Acute E. coli ST131 Bladder Infection Can Be Prevented Using
an Orally Administered FimH Inhibitor
The multidrug resistance of E. coli ST131 poses a challenge for
successful treatment and prevention of recurrent UTI, which
may be exacerbated by the formation of IBCs. E. coli EC958 is
resistant to 8 classes of antibiotics, including cephalosporins,
fluoroquinolones, and aminoglycosides. Consistent with this
phenotype, we showed that E. coli EC958 established acute
bladder infection in C3H/HeN mice (n = 8) that were given
prophylactic TMP-SMZ (54 or 270 μg/mL) for 3 days prior to
infection (Figure 4A). This result, when considered in light of
the widespread occurrence of multidrug-resistant UPEC infec-
tions, prompted us to evaluate alternative strategies for the
treatment and prevention of E. coli ST131–mediated UTI. We
have previously demonstrated that strains of the ST131 lineage,
including E. coli EC958, rely on the FimH adhesin of type 1
fimbriae for colonization of the mouse bladder [28]. Given the
key role of type 1 fimbriae in E. coli EC958 uropathogenesis, we
evaluated the efficacy of a previously characterized FimH inhib-
itor [21] in preventing acute bladder infection by E. coli EC958.
Two groups of 8 mice were administered 1 oral dose of com-
pound ZFH-04269 (50 mg/kg) or PBS 30 minutes prior to in-
traurethral inoculation with E. coli EC958 (107 CFU), and
bacterial titers in bladders and kidneys were assessed at 6 hours
after infection.Mice treated with compoundZFH-04269 showed
Figure 3. Escherichia coli ST131 causes chronic cystitis in female C3H/HeN mice. A, Schematic of the experimental time line used to study chronic in-
fection caused by E. coli EC958. Two groups of 20 mice were inoculated with E. coli EC958 at 107 or 108 colony-forming units (CFU), and longitudinal urinal-
ysis was performed over a period of at least 4 weeks to identify mice with persistent bacteriuria (PB; B and C, respectively). Dots connected by lines
represent longitudinal urine E. coli EC958 titers for each mouse; black circles represent mice with PB (>104 CFU/mL at every time point assessed), and
white circles represent mice that resolved bacteriuria (<104 CFU/mL at least once during the assessment period). D, Bacterial titers in urine (U), bladder
(B), and kidneys (K; in CFU/mL or CFU/organ) of mice infected with E. coli EC958 (108 CFU inoculating dose). Data are presented for each mouse in which
bacteriuria resolved (n = 10) or PB developed (n = 5).
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a median 100-fold decrease in E. coli EC958 CFU in their
bladder, compared with PBS-treated control mice (P = .0009,
by the Mann–Whitney U test; Figure 4B). No difference was
observed in E. coli EC958 bacterial titers in the kidneys of mice
treated with compound ZFH-04269 or PBS (Figure 4B). These
data highlight the importance of type 1 fimbriae in the estab-
lishment of cystitis by E. coli EC958 and indicate that FimH in-
hibitors may be a promising strategy for preventing infection
by multidrug-resistant E. coli ST131.
A FimH Inhibitor Can Successfully Treat Bladder Infection in
Mice Chronically Infected With E. coli ST131
We also evaluated the efficacy of compound ZFH-04269 in
treating established bladder infection in mice with chronic cys-
titis. Sixty mice were infected with E. coli EC958 (108 CFU) and
in 2 independent experiments and mice with chronic infection
(urine bacterial titers of >104 CFU over a 14-day period;
n = 26) were treated with 1 oral dose of compound ZFH-04269
(n = 13) or PBS (n = 13) at day 14 after infection. Enumeration
of bladder bacterial titers 6 hours after treatment revealed that
the median number of E. coli EC958 CFU per bladder in mice
treated with ZFH-04269 was >1000-fold less than that in PBS-
treated controls (P = .0018, by the Mann–Whitney U test;
Figure 4C). Moreover, the median E. coli EC958 load in the
bladder of mannoside-treated mice was reduced to <104 CFU
(P = .0398, by the Wilcoxon signed rank test), which is closer to
the median bacterial titer observed in the bladders of mice that
resolved bacteriuria (Figure 3D). No effect was observed for
compound ZFH-04269 treatment on kidney colonization
(Figure 4C).
DISCUSSION
Several recent publications, including reports from the Infectious
Diseases Society of America, highlight the urgent need for new
therapies to combat multidrug-resistant gram-negative patho-
gens, including E. coli ST131 [3, 37–39]. E. coli ST131 is a high-
risk ESBL-producing clone and currently represents one of the
Figure 4. One oral dose of a FimH inhibitor significantly decreases the bacterial load in the bladder of C3H/HeN mice infected with Escherichia coli
ST131. A and B, Bacterial titers in bladder and kidneys of mice infected with E. coli EC958 at 6 hours after infection. A, Groups of 8 mice each were given
either trimethoprim-sulfamethoxazole (TMP-SMZ) in the drinking water (54 and 270 μg/mL, respectively; white circles) or were left untreated (black
circles) for 3 days prior to infection. B, Groups of 8 mice each were administered 1 dose of compound ZFH-04269 orally (50 mg/kg; white circles) or phos-
phate-buffered saline (PBS; black circles) by oral gavage 30 minutes prior to E. coli EC958 infection C, E. coli EC958 titers in bladder and kidneys of mice
with persistent bacteriuria at day 14 after infection. Groups of 13 mice each were administered a single dose of compound ZFH-04269 (50 mg/kg; white
circles) or PBS (black circles) by oral gavage. Mice were euthanized 6 hours following treatment. Group median values are shown as horizontal lines.
926 • JID 2013:208 (15 September) • Totsika et al
Downloaded from https://academic.oup.com/jid/article-abstract/208/6/921/831769
by guest
on 10 March 2018
most dominant groups of multidrug-resistant E. coli strains in-
ternationally [40].While many studies have examined the resis-
tance profiles of E. coli ST131, little is known about the factors
that contribute to the clone’s pathogenesis. We recently dem-
onstrated that E. coli ST131 isolates establish acute bladder
infection in C57BL/6J mice in a type 1 fimbriae–dependent
manner [28]. In this study, we mapped the pathogenic lifestyle
of E. coli ST131 in much greater detail, using a C3H/HeNmouse
infection model, and we evaluated for the first time alternative
strategies for the treatment of E. coli ST131–mediated UTI.
E. coli EC958 is a representative isolate from the ST131 lineage
and is resistant to multiple classes of antibiotics, including
cephalosporins, fluoroquinolones, sulfonamides, and amino-
glycosides [28]. Using a well-established mouse model of UTI,
we show here that E. coli EC958 invades urothelial cells of the
mouse bladder and forms IBCs with a size and morphology
comparable to those of the reference cystitis strain E. coli
UTI89 [10]. Moreover, the progression of E. coli EC958
through the IBC developmental cycle in the C3H/HeN mouse
bladder mirrored closely the timing previously observed for E.
coli UTI89 in the same mouse model [12]. This study also de-
scribes the first analysis of E. coli ST131 infection in a chronic
UTI model and will provide a framework to further understand
these infections. Given that E. coli strains EC958 and UTI89 are
as distantly related at the whole-genome level as E. coli EC958
is to E. coli strains belonging to other phylogroups (eg, A and
D) and other pathotypes (eg, commensal and enterohemorrha-
gic E. coli; Totsika and Beatson, unpublished data), it is perhaps
surprising that the pathogenesis of E. coli EC958 and UTI89 in
the mouse bladder is so closely matched. This would support
recent findings suggesting that UPEC strains that have different
virulence profiles but express type 1 fimbriae induce a conver-
gent host response involving pathways such as IBC formation
that result in common symptoms of cystitis [41].
The inability to effectively combat infections caused by mul-
tidrug-resistant E. coli with currently available therapies is a
pressing medical concern, and alternative therapeutic strategies
are needed. Inhibiting the function of virulence factors required
by pathogens to cause disease, such as the FimH adhesin in
the case of UPEC, is an attractive alternative approach to antibi-
otic therapies [42]. A previously characterized biphenyl FimH
inhibitor (previously termed compound 8 [21] and herein
referred to by its official nomenclature as compound ZFH-
04269) was selected for in vivo efficacy evaluation against E.
coli ST131 strain EC958 because of its enhanced potency and
oral bioavailability [21]. Administration of 1 oral dose of com-
pound ZFH-04269 to female mice chronically infected with
E. coli EC958 resulted in significant bacterial clearance in the
bladder within 6 hours. In addition, 1 prophylactic dose of
compound ZFH-04269 given orally to mice 30 minutes before
intraurethral inoculation with E. coli EC958 was protective
against acute cystitis, in contrast to TMP-SMZ, which was
completely ineffective. As C3H mice are genetically susceptible
to vesicoureteral reflux, kidney colonization occurs early in ex-
perimental UTI, independent of bladder colonization [35, 36].
Therefore, as expected, treatment with ZFH-04269 had no
effect on kidney colonization, which is typically not dependent
on type 1 fimbriae. However, in uncomplicated cystitis, which
accounts for the vast majority of UTI, pyelonephritis is a rare
complication (incidence, <1% in placebo-treated patients [3]),
and preventing and/or successfully treating initial bladder colo-
nization would be expected to fully prevent or cure UTI.
The high efficacy of the ZFH-04269 FimH inhibitor as both
a treatment and prevention strategy in small-animal models of
cystitis paves the way for further work to test different dosing
regimens, including extended therapy and combination therapy
with antibiotics, and to examine the effect of this compound on
gut colonization by both E. coli ST131 and other gram-negative
bacteria. If our results are clinically translatable to humans, they
provide strong evidence that FimH inhibitors could effectively
prevent and treat bladder infections caused by multidrug-
resistant E. coli ST131 and reduce the need for prescribing
broad-spectrum antibiotics to treat community-acquired UTI.
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